Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 25

1.

QRS duration predicts death and hospitalization among patients with atrial fibrillation irrespective of heart failure: evidence from the AFFIRM study.

Whitbeck MG, Charnigo RJ, Shah J, Morales G, Leung SW, Fornwalt B, Bailey AL, Ziada K, Sorrell VL, Zegarra MM, Thompson J, Hosn NA, Campbell CL, Gurley J, Anaya P, Booth DC, Di Biase L, Natale A, Smyth S, Moliterno DJ, Elayi CS; AFFIRM investigators.

Europace. 2014 Jun;16(6):803-11. doi: 10.1093/europace/eut335. Epub 2013 Dec 23.

2.

Increased survival with enzalutamide in prostate cancer after chemotherapy.

Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, de Wit R, Mulders P, Chi KN, Shore ND, Armstrong AJ, Flaig TW, Fl├ęchon A, Mainwaring P, Fleming M, Hainsworth JD, Hirmand M, Selby B, Seely L, de Bono JS; AFFIRM Investigators.

N Engl J Med. 2012 Sep 27;367(13):1187-97. Epub 2012 Aug 15.

3.

Comparison of rate versus rhythm control for atrial fibrillation in patients with left ventricular dysfunction (from the AFFIRM Study).

Freudenberger RS, Wilson AC, Kostis JB; AFFIRM Investigators and Committees.

Am J Cardiol. 2007 Jul 15;100(2):247-52. Epub 2007 Jun 4.

PMID:
17631079
4.

MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS.

Miller DH, Soon D, Fernando KT, MacManus DG, Barker GJ, Yousry TA, Fisher E, O'Connor PW, Phillips JT, Polman CH, Kappos L, Hutchinson M, Havrdova E, Lublin FD, Giovannoni G, Wajgt A, Rudick R, Lynn F, Panzara MA, Sandrock AW; AFFIRM Investigators.

Neurology. 2007 Apr 24;68(17):1390-401.

PMID:
17452584
5.

Infusion-related hypersensitivity reactions during natalizumab treatment.

Phillips JT, O'Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, Polman CH, Lublin FD, Giovannoni G, Wajgt A, Lynn F, Panzara MA, Sandrock AW; AFFIRM Investigators.

Neurology. 2006 Nov 14;67(9):1717-8. No abstract available. Erratum in: Neurology. 2007 Feb 6;68(6):473.

PMID:
17101921
6.

Does intensity of rate-control influence outcome in atrial fibrillation? An analysis of pooled data from the RACE and AFFIRM studies.

Van Gelder IC, Wyse DG, Chandler ML, Cooper HA, Olshansky B, Hagens VE, Crijns HJ; RACE and AFFIRM Investigators.

Europace. 2006 Nov;8(11):935-42. Epub 2006 Sep 14.

PMID:
16973686
7.

Perceived effects on patients' health of participation in the atrial fibrillation follow-up investigation of rhythm management study.

Kellen JC, Schron EB, Milne J, Chandler ML, Berg CM, Ritchie DA, Paterson D, Sweeney PA, Nelson JD, Mickel M; AFFIRM Investigators and Coordinators.

J Cardiovasc Nurs. 2006 Sep-Oct;21(5):388-96.

PMID:
16966916
8.

Atrial fibrillation among African Americans, Hispanics and Caucasians: clinical features and outcomes from the AFFIRM trial.

Bush D, Martin LW, Leman R, Chandler M, Haywood LJ; NHLBI AFFIRM Investigators.

J Natl Med Assoc. 2006 Mar;98(3):330-9.

9.

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis.

Polman CH, O'Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, Phillips JT, Lublin FD, Giovannoni G, Wajgt A, Toal M, Lynn F, Panzara MA, Sandrock AW; AFFIRM Investigators.

N Engl J Med. 2006 Mar 2;354(9):899-910.

10.

Prediction of the recurrence of atrial fibrillation after cardioversion in the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study.

Raitt MH, Volgman AS, Zoble RG, Charbonneau L, Padder FA, O'Hara GE, Kerr D; AFFIRM Investigators.

Am Heart J. 2006 Feb;151(2):390-6.

PMID:
16442905
11.

Functional status in rate- versus rhythm-control strategies for atrial fibrillation: results of the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Functional Status Substudy.

Chung MK, Shemanski L, Sherman DG, Greene HL, Hogan DB, Kellen JC, Kim SG, Martin LW, Rosenberg Y, Wyse DG; AFFIRM Investigators.

J Am Coll Cardiol. 2005 Nov 15;46(10):1891-9. Epub 2005 Oct 21.

12.

Comparison of management patterns and clinical outcomes in patients with atrial fibrillation in Canada and the United States (from the analysis of the Atrial Fibrillation Follow-up Investigation of Rhythm Management [AFFIRM] database).

O'Hara GE, Charbonneau L, Chandler M, Vidaillet HJ Jr, Philippon F, Sami M, Rocco TA Jr, Padder FA, Champagne J, Pratt CM, Coutu B, Wyse DG; AFFIRM Investigators.

Am J Cardiol. 2005 Sep 15;96(6):815-21.

PMID:
16169368
13.

Asymptomatic atrial fibrillation: demographic features and prognostic information from the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study.

Flaker GC, Belew K, Beckman K, Vidaillet H, Kron J, Safford R, Mickel M, Barrell P; AFFIRM Investigators.

Am Heart J. 2005 Apr;149(4):657-63.

PMID:
15990749
14.

Factors affecting bleeding risk during anticoagulant therapy in patients with atrial fibrillation: observations from the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study.

DiMarco JP, Flaker G, Waldo AL, Corley SD, Greene HL, Safford RE, Rosenfeld LE, Mitrani G, Nemeth M; AFFIRM Investigators.

Am Heart J. 2005 Apr;149(4):650-6.

PMID:
15990748
15.

Clinical factors that influence response to treatment strategies in atrial fibrillation: the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study.

Curtis AB, Gersh BJ, Corley SD, DiMarco JP, Domanski MJ, Geller N, Greene HL, Kellen JC, Mickel M, Nelson JD, Rosenberg Y, Schron E, Shemanski L, Waldo AL, Wyse DG; AFFIRM Investigators.

Am Heart J. 2005 Apr;149(4):645-9.

PMID:
15990747
16.

Occurrence and characteristics of stroke events in the Atrial Fibrillation Follow-up Investigation of Sinus Rhythm Management (AFFIRM) study.

Sherman DG, Kim SG, Boop BS, Corley SD, Dimarco JP, Hart RG, Haywood LJ, Hoyte K, Kaufman ES, Kim MH, Nasco E, Waldo AL; National Heart, Lung, and Blood Institute AFFIRM Investigators.

Arch Intern Med. 2005 May 23;165(10):1185-91.

PMID:
15911734
17.

Inhibition of angiotensin II signaling and recurrence of atrial fibrillation in AFFIRM.

Murray KT, Rottman JN, Arbogast PG, Shemanski L, Primm RK, Campbell WB, Solomon AJ, Olgin JE, Wilson MJ, Dimarco JP, Beckman KJ, Dennish G, Naccarelli GV, Ray WA; AFFIRM Investigators.

Heart Rhythm. 2004 Dec;1(6):669-75.

PMID:
15851238
18.

Alternative endpoints for mortality in studies of patients with atrial fibrillation: the AFFIRM study experience.

Wyse DG, Slee A, Epstein AE, Gersh BJ, Rocco T Jr, Vidaillet H, Volgman A, Weiss R, Shemanski L, Greene HL; AFFIRM Investigators.

Heart Rhythm. 2004 Nov;1(5):531-7.

PMID:
15851214
19.

Relation of initial resting ventricular rate to the ability to achieve and maintain normal sinus rhythm in patients with atrial fibrillation.

Cooper HA, Sacco J, Solomon AJ, Feld GK, Leman R, Wilber D; AFFIRM Investigators.

Am J Cardiol. 2005 Mar 1;95(5):597-602.

PMID:
15721098
20.

Use of amiodarone for atrial fibrillation in patients with preexisting pulmonary disease in the AFFIRM study.

Olshansky B, Sami M, Rubin A, Kostis J, Shorofsky S, Slee A, Greene HL; NHLBI AFFIRM Investigators.

Am J Cardiol. 2005 Feb 1;95(3):404-5.

PMID:
15670555

Supplemental Content

Loading ...
Support Center